
Claire Bewshea

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2857557/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
2	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology, 2020, 158, 189-199.	1.3	249
3	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 2021, 70, 1884-1893.	12.1	233
4	HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	21.4	165
5	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 2021, 70, 865-875.	12.1	153
6	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	7.4	129
7	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology and Hepatology, 2022, 7, 342-352.	8.1	100
8	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 149-158.	1.3	85
9	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
10	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. Journal of Crohn's and Colitis, 2022, 16, 389-397.	1.3	39
11	Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1103-1116.	3.7	31
12	Incidence and prevalence of inflammatory bowel disease in Devon, UK. Frontline Gastroenterology, 2021, 12, 461-470.	1.8	18
13	Quality improvement project identifies factors associated with delay in IBD diagnosis. Alimentary Pharmacology and Therapeutics, 2020, 52, 471-480.	3.7	14
14	Validating the positivity thresholds of drugâ€ŧolerant antiâ€infliximab and antiâ€adalimumab antibody assays. Alimentary Pharmacology and Therapeutics, 2021, 53, 128-137.	3.7	9
15	Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Annals of Clinical Biochemistry, 2015, 52, 672-674.	1.6	6
16	Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. Journal of Medical Ethics, 2016, 42, 695-697.	1.8	5
17	Understanding <scp>antiâ€TNF</scp> treatment failure: does serum triiodothyronineâ€ŧoâ€ŧhyroxine (<scp>T3</scp> / <scp>T4</scp>) ratio predict therapeutic outcome to <scp>antiâ€TNF</scp> therapies in biologicâ€naĂ⁻ve patients with active luminal Crohn's disease?. Alimentary Pharmacology and Therapeutics. 2022, 56, 783-793.	3.7	5
18	Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Archives of Disease in Childhood, 2020, 105, 957-963.	1.9	4

#	Article	IF	CITATIONS
19	OC-050â€5-Aminosalicylate (5-Asa) Induced Nephrotoxicity in Inflammatory Bowel Disease. Gut, 2013, 62, A22.1-A22.	12.1	3
20	PTU-010â€Prevalence and phenotype of IBD across primary and secondary care: implications for colorectal cancer surveillance. , 2018, , .		0
21	Ethical issues in genomic research: Proposing guiding principles co-produced with stakeholders. Clinical Ethics, 2018, 13, 194-198.	0.7	0